use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration

摘要

An non absorbable antibiotic, anti-arthritogenic peptide antibody or rheumatoid arthritis (RA) benign bacteria is used in the manufacture of a medicament for reducing exposure to arthritogenic peptides of a person who has RA or is predisposed to develop RA by either: a) administering a therapeutically effective dosage of nonabsorbable antibiotic enterally to the person b) administering a therapeutically effective dosage of peptide antibody or c) administering a therapeutically effective dosage of RA benign bacteria to the person.